Vicente Valero

TL;DR: Continuous RCB index was prognostic for long-term survival after neoadjuvant chemotherapy in all three phenotypic subsets of breast cancer and stratified prognostic risk overall, within each phenotypesic subset, and within yp-stage categories.

TL;DR: In this article, the authors reported a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and paclitaxel, followed by concurrent Trastuzumaab and 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) preoperative chemotherapy.

TL;DR: The change in schedule of paclitaxel from once every 3 weeks to a more frequent administration significantly improved the ability to eradicate invasive cancer in the breast and lymph nodes.

TL;DR: The combination of bevacizumab with commonly used chemotherapies improved PFS in the second-line treatment of patients with HER2-negative metastatic breast cancer, with a safety profile comparable with that in prior phase III studies.

TL;DR: AlN pCR is associated with an excellent prognosis, even with a residual primary tumor, pointing to biologic differences between primary and metastatic cells, and patients who do not benefit from neoadjuvant anthracyclines are unlikely to benefit from subsequent taxanes.